Objective To evaluate the effect of ritodrine sustained release capsules for maintaining uterine quiescence after successful treatment of active preterm labour.
INTRODUCTION
wished to examine whether the use of this sustained There is some evidence from controlled studies please preparation would be sufficiently effective in reducing recurrences of preterm labour to warrant its use in clinical practice. inhibition of preterm labour with betamimetics is more likely to be effective when intravenous treatment is followed by oral main tenance than when it is not. That evidence is weak, however, and spread across three small studies not all of which used the same betamimetic agent1 3. Among them they only showed fewer relapses and longer relapse free intervals, but no reduction in the incidence of preterm . These not particularly impressive effects required the fre quent intake of a large number of tablets to compensate for the low bioavailability and short half-lives of oral betamimeticsfl.
The use of ritodrine in a sustained release formulation permits the limitation of betamimetic intake to three times a day while obtaining plasma levels that parallel the lower range of effective intravenous treatment7 with few side effects7,8. We 
METHODS
A placebo-controlled comparison of ritodrine sustained release capsules for maintaining uterine quiescence after arrest of preterm labour was conducted with approval at five Dutch teaching hospitals. Women recruited for the study were those who had participated in a randomized comparison of two schedules of intravenous ritodrine administration, described elsewhere", and in whom this had resulted in the arrest of active preterm labour. Of the 143 women in whom preterm labour had been stopped with either one of two ritodrine schedules, 18 were not eligible because they had received indomethacin (n had ruptured membranes (n = 2), had experienced severe side effects during intravenous treatment (« = 4), or were beyond 34 {n = ô)". Of the 125 women who were eligible, 30 did not participate in the present study: 16 because venous treatment or leading to delivery, or after they received active treatment without blinding; seven days. Other tocolytic agents were not used. eight because of transfer to a nonparticipating
The main outcome parameters were adminhospital or lack of consent; and six for reasons istration of another course of intravenous tocolysis that were not documented. Thus, 95 women and delivery during the seven days of maintenance participated in the trial; 50 of them had originally treatment. Additional predefined outcomes were: received the loading and 45 the incremental dose number of deliveries before 35 and 37 weeks and schedule of intravenous treatment9 (Table 1) number of deliveries during treatment (Table 2) . adrenergic receptors to betamimetic agents13. Still There were no other statistically significant differothers reflect concepts, such as down-regulation of ences between the groups; neither in duration of 6-adrenergic receptors 15, 16 that may limit the hospitalisation, gestational age at delivery or utility of long-term tocolysis, or beliefs that incidence o f side effects (Table 2 ). In only one tocolytic treatments are symptomatic in nature woman (in the ritodrine group) treatment was and thence superfluous when symptoms are no stopped because o f side effects (headache; Table 2 ). longer present. These many persuasions gain a There was one case o f abruption four days after great deal o f impetus from the limited bio stopping placebo treatment and one death: an availability of betamimetics after oral adminisunexplained intrauterine death of a mature infant tration and the short half-lives which require two months after the end of the trial (ritodrine tablets to be taken at frequent intervals throughout group) and a further 27 days of open oral ritodrine the day and night, if pharmacological credibility is treatment. Except for this death and one mother to be sustained3,6,8,13. Yet, many clinicians feel who could not be traced after moving to another something incongruous in waking a woman, who city, all mothers and infants were well at follow up is finally asleep after the uterus has been subdued. in the postneonatal period. DISCUSSION merely to maintain the status quo so that she can sleep again.
Oral preparations of ritodrine have a bioAlthough virtually all controlled trials of betaavailability of about 30% 7,17 , and they must be mimetic agents in the treatment of preterm labour taken 6 times a day in order to maintain reasonable have incorporated an episode of maintenance plasma levels18. It has been argued that the low treatment11,12, there is divergence of opinion efficacy of the medication is often due to inbetween countries and individual obstetricians adequate plasma levels6. With the sustained release on whether maintenance treatment is worthwhile capsules three doses of 80 mg a day are sufficient after arrest of active preterm labour13,14. There to obtain plasma levels that are equivalent to are many reasons for this, not the least of which those obtained with an intravenous infusion of is lack of evidence that such treatment reduces the 50 |Ag/min ritodrine without serious side effects7,19, preterm birth rate4,5. Other reasons relate to a The fact that only one of 95 women in our study wide range of potential, albeit mainly hypothetical failed to comply with the prescribed maintenance s of prolonged exposure of fetal betaof three doses a day suggests that this treatment is
